Clinical trials: Cerebral Vascular Disorder
Acute Ischemic Stroke
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study.
- Trial name
- ACTISAVE (NCT05070260)
- Testing
- Intravenous glenzocimab (ACT017) 1000 mg
- Where
- 10 sites in United States, Germany
- Volunteers
- 438 people
- Sponsor
- Acticor Biotech
Cerebral Infarction
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects
- Trial name
- NCT02378974
- Testing
- Cordstem-ST
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CHABiotech CO., Ltd
Acute Ischemic Stroke
A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
The primary purpose of this trial is to compare the efficacy of different doses of investigator product and comparator product in patients with acute ischemic stroke in 4.5 Hours after stroke onset, and provide a basis of drug…
- Trial name
- NCT04028518
- Testing
- r-PA, Alteplase for Injection
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
Stroke, Systemic Embolism, VTEt and VTEp
Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries
The main purpose is to evaluate the effectiveness of the Eliquis® (apixaban) Prescriber Guide and Patient Alert Card in terms knowledge of the important identified risk of bleeding associated with Eliquis treatment communicated…
- Trial name
- NCT02339818
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke
A Safety Evaluation of the Use of Magnetic-guided Iron Particles
This study is a prospective trial wherein each included subject will receive the experimental magnetically enhanced diffusion therapy.
- Trial name
- NCT01519076
- Testing
- Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)
- Where
- 2 sites in Australia
- Volunteers
- 7 people
- Sponsor
- Pulse Therapeutics
Chronic Stroke, Motor Disorders
Immersive Virtual Reality for Stroke Motor Rehabilitation
The present study aims at investigating (i) the feasibility in chronic stroke of using a dedicated virtual reality (VR) based system that embeds real-time 3D motion capture and embodied visual feedback to deliver functional…
- Trial name
- NCT03094650
- Testing
- MindMotion PRO
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Mindmaze SA
Ischemic Stroke
Stent Retriever's(TonbridgeMT) Endovascular Therapy for Acute Ischemic Stroke(AIS)
The study is a prospective, multi-center, stratified randomized, single-blind, parallel assignment, active control, non-inferiority trial.
- Trial name
- NCT03210623
- Testing
- stent retriever(TonbridgeMT), Solitaire™
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Ton-Bridge Medical Tech. Co., Ltd
Atrial Fibrillation
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting
- Trial name
- RIVA-F (NCT02690155)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
- Where
- United States
- Volunteers
- 38,831 people
- Sponsor
- Bayer
Tachycardia Atrial, Atrial Fibrillation
BIO|STREAM.ICM Obesity
The aim of the submodule study is to assess whether a high BMI may influence the sensing performance and the sECG quality of the BIOMONITOR.
- Conditions
- Tachycardia Atrial, Atrial Fibrillation, Syncope, Bradycardia
- Trial name
- NCT04198220
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Biotronik SE & Co. KG
Stroke
Evaluation of Transfer Kinematics and Kinetics in Patients Chronic Post-stroke Using the Tibion Bionic Leg
The objective of this clinical study is to examine the acute kinematics and kinetics of utilizing the Tibion Bionic Leg in a sample of chronic post-stroke patients performing sit-to-stand and stand-to-sit transfers across a range…
- Trial name
- NCT01626417
- Testing
- Tibion Bionic Leg
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Tibion Bionics, Inc.
Fabry Disease
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. This study includes a sub-study evaluating kidney Gb3 inclusions (and other histologic lesions) in male…
- Trial name
- NCT03737214
- Testing
- Lucerastat
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 107 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Stroke, Stroke Acute
Research on the Effectiveness of Neurorehabilitation After Stroke
This clinical trial aims to investigate the effectiveness of a novel neurorehabilitation technology for treating stroke in adults.
- Conditions
- Stroke, Stroke Acute, Stroke with Hemiparesis, Stroke, Acute
- Trial name
- NCT06753006
- Testing
- Neurorehabilitation simulator, Standard course
- Where
- Russia
- Volunteers
- 44 people
- Sponsor
- Neurotechnika
Atrial Fibrillation
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
Apixaban is a direct anticoagulant, which inhibits the factor Xa. Its clinical efficiency in prevention of stroke and systemic embolism in adult patients with NVAF (non/valvular atrial fibrillation) was demonstrated as well as…
- Trial name
- SPAF (NCT03441633)
- Testing
- apixaban, dabigatran, VKA
- Where
- Spain
- Volunteers
- 51,690 people
- Sponsor
- Pfizer
Fabry Disease
French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat
This is a noninterventional cohort study to evaluate the effects of migalastat, on long-term safety, effectiveness, and quality of life (QOL) in patients with Fabry disease.
- Trial name
- NCT04602364
- Testing
- Noninterventional
- Where
- 13 sites in France
- Volunteers
- 48 people
- Sponsor
- Amicus Therapeutics France SAS
Brain Aneurysm
Aneurysm Study of Pipeline in an Observational Registry
The primary objective of this study is to further expand the body of clinical knowledge in patients undergoing Pipeline Embolization Device (Pipeline or PED) placement for intracranial aneurysms (IAs or ICAs) according to…
- Trial name
- ASPIRE (NCT01557036)
- Testing
- Pipeline Embolization Device
- Where
- 36 sites in United States, Argentina and 6 more
- Volunteers
- 200 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Stroke
WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.
- Trial name
- WAVECREST2 (NCT03302494)
- Testing
- Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
- Where
- 25 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- Coherex Medical
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Chronic Cluster Headache
Cephalic Vascular Recording Upon SPG Stimulation
Hypothesis: Stimulation of the SPG at high frequencies (50-200Hz) is believed to cause a physiological parasympathetic block which decreases VMCA oxyHb concentration and cephalic vessel diameter.
- Trial name
- NCT01359631
- Volunteers
- 7 people
- Sponsor
- Autonomic Technologies, Inc.
Vascular Dementia
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
This clinical trial was performed to assess the clinical efficacy and safety of two 4 week treatment courses of daily intravenous administration of Cerebrolysin (20mL [milliliter] IV [intravenous] per day).
- Trial name
- VascDem (NCT00947531)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 21 sites in Russia
- Volunteers
- 242 people
- Sponsor
- Ever Neuro Pharma GmbH
Stroke
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
The objective of this study is to assess the safety, tolerability and pharmacokinetic characteristics of BIII 890 after intravenous infusion in acute ischemic stroke patients.
- Trial name
- NCT02251197
- Testing
- BIII 890 CL
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.